Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-03-20
2007-03-20
Carlson, Karen Cochrane (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S252300, C435S325000, C536S023100, C530S350000
Reexamination Certificate
active
10936059
ABSTRACT:
IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided.
REFERENCES:
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5212074 (1993-05-01), Kiefer et al.
patent: 5258287 (1993-11-01), Baxter et al.
patent: 5328891 (1994-07-01), Baxter et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5840673 (1998-11-01), Buckbinder et al.
patent: 5973115 (1999-10-01), Clemmons et al.
patent: 6004775 (1999-12-01), Shimasaki et al.
patent: 6025465 (2000-02-01), Kiefer et al.
patent: 6121416 (2000-09-01), Clark et al.
patent: 6251865 (2001-06-01), Clark et al.
patent: 6369029 (2002-04-01), Andress et al.
patent: 6391588 (2002-05-01), Andress et al.
patent: 6410335 (2002-06-01), Pollak et al.
patent: 6417330 (2002-07-01), Mascarenhas et al.
patent: 6489294 (2002-12-01), Andress et al.
patent: 6500635 (2002-12-01), Kiefer
patent: 2001/0018190 (2001-08-01), Pollak et al.
patent: 2002/0072589 (2002-06-01), Mascarenhas et al.
patent: 2003/0059430 (2003-03-01), Mascarenhas
patent: 2003/0082744 (2003-05-01), Kiefer
patent: 2003/0092631 (2003-05-01), Deshayes et al.
patent: 2003/0161829 (2003-08-01), Mascarenhas
patent: 0 230 869 (1987-08-01), None
patent: 0 294 021 (1988-12-01), None
patent: 0 375 438 (1990-06-01), None
patent: 0 369 943 (1990-09-01), None
patent: 0 546 053 (1993-06-01), None
patent: 1 295 939 (2003-03-01), None
patent: WO 89/08667 (1989-09-01), None
patent: WO 89/09268 (1989-10-01), None
patent: WO 89/09792 (1989-10-01), None
patent: WO 90/00569 (1990-01-01), None
patent: WO 92/03152 (1992-03-01), None
patent: WO 92/03469 (1992-03-01), None
patent: WO 92/03470 (1992-03-01), None
patent: WO 92/03471 (1992-03-01), None
patent: WO 92/12243 (1992-07-01), None
patent: WO 92/14834 (1992-09-01), None
patent: WO 93/23067 (1993-11-01), None
patent: WP 94/22466 (1994-10-01), None
patent: WO 97/09998 (1997-03-01), None
patent: WO 99/32620 (1999-07-01), None
patent: WO 99/63086 (1999-12-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 00/35473 (2000-06-01), None
patent: WO 01/72771 (2001-10-01), None
patent: WO 01/75064 (2001-10-01), None
patent: WO 01/87238 (2001-11-01), None
patent: WO 02/34916 (2002-05-01), None
patent: WO 02/098914 (2002-12-01), None
patent: WO 03/006029 (2003-01-01), None
patent: WO 03/025121 (2003-03-01), None
patent: WO 03/052079 (2003-06-01), None
patent: WO 03/068160 (2003-08-01), None
Andress and Birnbaum, “A novel human insulin-like growth factor binding protein secreted by osteoblast-like cells”Biochim. Biophys. Res Com. 176:213-218 (1991).
Angelloz-Nicoud et al., “Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160) and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-like growth factor binding protein-3”Growth Hormone&IGF Research8:71-75 (1990).
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews. 3(1):38-61 (1995).
Bagley et al., “A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide”Biochemical Journal259(3):665-671 (May 1, 1989).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I.”Endocrinology. 127(6):3243-3245 (1990).
Baxter & Martin, “Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins”Biochem.&Biophys. Res. Comm. 147(1):408-415 (1987).
Baxter et al., “Growth Hormone-Dependent Insulin-Like Growth Factor (IGF) Binding Protein from Human Plasma Differs from Other Human IGF Binding Proteins”Biochem.&Biophys. Res. Comm. 139(3):1256-1261 (1986).
Baxter et al., “Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily”Endocrinology139(10):4036 (Oct. 1998).
Baxter et al., “Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3”Journal of Biological Chemistry267(1):60-65 (Jan. 5, 1992).
Baxter, R., “The Insulin-Like Growth Factors and Their Binding Proteins”Comp. Biochem. Physiol. 91B(2):229-235 (1988).
Bayne et al., “Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 263:6233-6239 (1988).
Bayne et al., “The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor.”J. Bio. Chem. 264(19):11004-11008 (1988).
Bayne et al., “The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 265(26):15648-15652 (Sep. 15, 1990).
Bernard et al., “The amino-terminal region of insulin-like growth factor binding protein-3, 1 95 IGFBP-3, induces apoptosis of MCF-7 breast carcinoma cells”Biochem.&Biophys. Res. Comm. 293:55-60 (2002).
Binkert et al., “Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)”EMBO Journal8:2497-2502 (1989).
Blundell et al., “Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding.”Proc. Natl. Acad. Sci. USA75(1):180-184 (Jan. 1978).
Blundell et al., “Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors.”Federation Proc. 42:2592-2597 (1983).
Brewer et al., “Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein”Biochem.&Biophys. Res. Comm. 152(3):1289-1297 (1988).
Brinkman et al., “Isolation and charcterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)”The EMBO J. 7:2417-2423 (1988).
Campbell et al., “Insulin-like Growth Factor-binding Protein-3 Binds Fibrinogen and Fibrin”Journal of Biological Chemistry274:30215-30221 (1999).
Campbell et al., “Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3”Am. J. Physiol. 275:E321-E231 (1998).
Carter, “American Chemical Society Symposium Series No. 427”Protein Purification: From Molecular Mechanisms to Large-Scale Processes., Ladisch et al., Eds., Chapter 13, pp. 181-193 (1990).
Cascieri et al., “Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor.”Biochemistry27(9) :3229-3233 (May 3, 1988).
Cascieri et al., “Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors.”J. Bio. Chem. 264:2199-2202 (1989).
Chen et al., “A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum”Am. J. Physiol. Endocrinol. Metab. 284:E1149-E1155 (2003).
Chernausek et al., “Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4”Journal of Biological Chemistry270(19):11377-11382 (May 12, 1995).
Clark and Robinson, “Up and down the growth hormone cascade”Cytokine&Growth Factor Reviews7(1):65-80 (Jun. 1996).
Clemmons et al., “Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs.”Endocrinology. 131(2):890-895 (Aug. 1992).
Clemmons et al., “Discrete Alterations of the Insulin-Like Growth Fac
Lien Samantha
Lowman Henry
Carlson Karen Cochrane
Dreger, Esq. Ginger R.
Genentech Inc.
Hasak, Esq. Janet E.
Heller Ehrman LLP
LandOfFree
IGF binding proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF binding proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF binding proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773998